Clinical Trials

47 enrolled

Leukemia, Myeloid, Acute

NCT07137416 2026-05-27

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Phase 1 Not yet recruiting

36 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07509034 2026-05-27

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

Phase 1 Not yet recruiting

Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT07572136 2026-05-27

Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)

57 enrolled

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

22 enrolled 14 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

NCT01251874 2026-05-22

Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer

44 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01445509 2026-05-22

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

Phase 1 Completed

50 enrolled

Neoplasms

NCT01875601 2026-05-22

NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors

Phase 1 Completed

16 enrolled

CNSSarcoma

Brain Neoplasms, Neuroblastoma, Sarcoma

NCT02211768 2026-05-22

Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1

Phase 1 Completed

10 enrolled

CNSSarcoma

Neurofibromatoses, Neurofibrosarcoma

NCT03049462 2026-05-22

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists

100 enrolled

Other

Obesity, Polycystic Ovary Syndrome

NCT03366116 2026-05-22

5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors

65 enrolled

Neoplasms

NCT04633239 2026-05-22

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer

42 enrolled

Gynecologic

Recurrent Ovarian High Grade Serous Adenocarcinoma

NCT05886049 2026-05-22

Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene

MyeloidOther hematologic neoplasm

28 enrolled

Acute Myeloid Leukemia With KMT2A Rearrangement

NCT06066138 2026-05-22

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

DermatologicGastrointestinalSarcomaThoracic

30 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Alveolar Soft Part, Small Cell Lung Carcinoma

NCT06090669 2026-05-22

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

75 enrolled

Classical hematology

Congenital Bone Marrow Failure Syndromes

NCT06995872 2026-05-22

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

CNS

Neuroblastoma

NCT07055477 2026-05-22

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

60 enrolled

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT04235777 2026-05-20

Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

100 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Urogenital Neoplasms

NCT04585958 2026-05-20

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

55 enrolled

Neoplasm Metastasis

NCT04902443 2026-05-20

Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV

58 enrolled

Sarcoma

Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

36 enrolled

Neoplasm Metastasis

NCT03805932 2026-05-19

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

18 enrolled 15 charts

Leukemia, Hairy Cell

NCT04514497 2026-05-19

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

EndocrineGastrointestinalThoracic

29 enrolled 25 charts

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Phase 1 Suspended

42 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05172245 2026-05-18

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

46 enrolled

Head & Neck

Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

Phase 1 Suspended

33 enrolled

Neoplasm Metastasis

NCT05685602 2026-05-18

CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer

Phase 1 Suspended

43 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT06908096 2026-05-18

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

750 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

30 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT01947023 2026-05-14

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

23 enrolled

Head & Neck

Thyroid Neoplasms

NCT01955499 2026-05-13

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

39 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02160015 2026-05-13

Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery

LymphoidOther hematologic neoplasm

12 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

71 enrolled

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

152 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496663 2026-05-13

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

138 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

66 enrolled

GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

NCT02862275 2026-05-13

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Neoplasm Metastasis, Hematologic Neoplasms

NCT03041688 2026-05-13

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

58 enrolled

Leukemia, Myeloid, Acute

NCT03321643 2026-05-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

24 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03502733 2026-05-13

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

64 enrolled

Lymphoid

Lymphoma, Neoplasm Metastasis

NCT03528642 2026-05-13

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

CNSLymphoid

Astrocytoma, Lymphoma, Follicular

NCT03816345 2026-05-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

300 enrolled

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT03816358 2026-05-13

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer